Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 3, 2015, Pages 356-364

  Ben Horin, S ^a,b   Chowers, Y ^c   Ungar, B ^a   Kopylov, U ^a,b   Loebstein, R ^a,b   Weiss, B ^b,d   Eliakim, R ^a,b   Del Tedesco, E ^e   Paul, S ^e   Roblin, X ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Edmond and Lily Safra Children's Hospital   (Israel)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; FRANCE; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; ISRAEL; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; TIME; YOUNG ADULT;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FRANCE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; ISRAEL; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84936846009     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13268     Document Type: Article

References (22)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
2. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
4. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
5. Karmiris K, Paintaud G, Noman M, et al,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
6. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
7. Vande Casteele N, Ferrante M, Van Assche G, et al,. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; pii: S0016-5085(15)00253-X. doi: 10.1053/j.gastro.2015.02.031 [Epub ahead of print].
8. Louis E, Mary JY, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
9. Brooks AJ, Sebastian S, Cross SS, et al,. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission. J Crohns Colitis 2014; 5: pii: jjv000. PMID:25311864 [Epub ahead of print]
10. Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA,. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2209-17.
11. Vande Casteele N, Gils A, Singh S, et al,. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71.
12. Roblin X, Rinaudo M, Del Tedesco E, et al,. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014; 109: 1250-6.
13. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
14. Colombel JF, Feagan BG, Sandborn WJ, et al,. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349-58.
15. Ordas I, Mould DR, Feagan BG, et al,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
16. Ben-Horin S, Chowers Y,. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014; 11: 243-55.
17. Drobne D, Bossuyt P, Breynaert C, et al,. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol 2015; 13: 514-21.
18. Armuzzi A, Marzo M, Felice C, et al,. Long-term scheduled therapy with infliximab in inflammatory bowel disease: a single-centre observational study. Gastroenterology 2010; 5 (Suppl. 1): s691-2.
19. Waugh AW, Garg S, Matic K, et al,. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32: 1129-34.
20. Molnár T, Lakatos PL, Farkas K, et al,. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-33.
21. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Ostergaard TO, Seidelin JB,. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518-27.
22. Mooiweer E, Severs M, Schipper ME, et al,. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis 2015; 9: 50-5.